Author

T. McFall

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

E. C. Stites· 3 shared L. Sisk-Hackworth· 2 shared A. S. Shaw· 1 shared G. M. Wahl· 1 shared G. Mendiratta· 1 shared J. Huang· 1 shared J. J. Moresco· 1 shared J. K. Diedrich· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. C. Stites

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

RAF conformational autoinhibition and 14-3-3 proteins promote paradoxical activation

G. Mendiratta, K. Abbott, Y.-C. Li, J. Yu, J. Huang, M. N. Shokhirev, T. McFall, G. M. Wahl, E. C. Stites

The paper investigates paradoxical activation of RAF kinases, showing that 14-3-3 proteins enhance this effect by stabilizing RAF conformations and dimerization.

bioRxiv · Oct 29, 2021Cancer Biology

Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors

T. McFall, M. Trogdon, L. Sisk-Hackworth, E. C. Stites

The paper shows that combining KRAS G12C and EGFR inhibitors inhibits both mutant and wild-type RAS, explaining their effectiveness in colorectal cancer.

bioRxiv · Oct 7, 2021Cancer Biology

A Systems Mechanism for KRAS Mutant Allele Specific Responses to Targeted Therapy

T. McFall, J. K. Diedrich, M. Mengistu, S. L. Littlechild, K. V. Paskvan, L. Sisk-Hackworth, J. J. Moresco, A. S. Shaw, E. C. Stites

The paper investigates why KRAS G13D mutant colorectal cancers respond to anti-EGFR therapy despite general resistance, using computational models and experimental validation.

bioRxiv · Dec 10, 2018Cancer Biology